Digoxin Immune Fab
| Systematic (IUPAC) name | |
|---|---|
| Anti-digoxin antibody fragment | |
| Clinical data | |
| AHFS/Drugs.com | Consumer Drug Information |
| Pregnancy cat. | C (US) |
| Legal status | ? |
| Routes | IV infusion, injection |
| Pharmacokinetic data | |
| Half-life | 15 hours for DigiFab, 23 hours for Digibind |
| Excretion | Renal |
| Identifiers | |
| ATC code | V03AB24 |
| DrugBank | DB00076 |
| ChEMBL | CHEMBL1201588  |
| Chemical data | |
| Formula | C6394H9908N1698O2011S58 |
| Mol. mass | 144602.257 g/mol |
| (what is this?) (verify) | |
Digoxin Immune Fab (Ovine) is the generic name for an antidote for overdose of digitalis.[1] It is made from immunoglobulin fragments from sheep who have already been immunized with a digoxin derivative, digoxindicarboxymethoxylamine (DDMA). Its brand names include Digibind (mfg. by and GlaxoSmithKline) and DigiFab, (mfg. by BTG plc).
Pharmacology
It works by binding to the digoxin, rendering them unable to bind to their action sites on target cells. The complexes accumulate in the blood and are expelled by the kidney.
Contraindications
Although no contraindications have been noted, the patient must be closely monitored for anaphylactic shock, and anyone allergic to sheep protein, papain, bromelain, or papaya extracts (papain is used to cleave the antibody into Fab and Fc fragments) should not use Digoxin Immune Fab (Ovine). Because it is relatively new, no drug interaction studies have been performed yet.
References
- ↑ DiDomenico RJ, Walton SM, Sanoski CA, Bauman JL (2000). "Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity". J. Cardiovasc. Pharmacol. Ther. 5 (2): 77–85. doi:10.1053/XV.2000.5590. PMID 11150387.
External links
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||